This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DexCom Introduces Registry to Monitor Outcomes of G6 System
by Zacks Equity Research
DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
Why Is SurModics (SRDX) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health's BioReference Laboratories Introduces NGS Assay
by Zacks Equity Research
OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.
Baxter (BAX) Attains FDA De Novo Authorization for Theranova
by Zacks Equity Research
Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.
Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval
by Zacks Equity Research
Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care
Here's Why You Should Retain Inogen in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects
Smith+Nephew Unveils Digital Platform to Boost Patient Care
by Zacks Equity Research
With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
Here's Why You Should Retain HMS Holdings in Your Portfolio
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) , thanks to solid prospects.
Thermo Fisher Unveils Suite of Hematology-Oncology Solutions
by Zacks Equity Research
The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from Thermo Fisher's (TMO) new portfolio of hematology-oncology solutions.
Masimo Releases Favorable Study Results on Pulse Oximetry
by Zacks Equity Research
The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.
Why Hold Strategy is Apt for Varian Medical (VAR) Stock Now
by Zacks Equity Research
Investor confidence is high in Varian Medical (VAR) stock at the moment.
Here's Why You Should Add NextGen Stock to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol
by Zacks Equity Research
PerkinElmer's (PKI) Hand Sanitizer Analyzer can help lab professionals and scientists all over the world in their fight against COVID-19.
PerkinElmer Launches Workstations for Coronavirus Testing
by Zacks Equity Research
PerkinElmer's (PKI) scalable and modular explorer automated workstations simplify testing workflows, thereby expediting the process of SARS-CoV-2 RT-PCR testing.
Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness
by Zacks Equity Research
The FDA approval of Masimo's (MASI) PVi system will enable patient safety.
Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.
SurModics (SRDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 110.00% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add AMN Healthcare to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.